The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
aPALACE 1-3 pooled analysis. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.
Patients treated with OTEZLA 30 mg BID achieved significantly greater improvement vs placebo in dactylitis count (mean change of -1.8 vs -1.3, P<0.01) at week 242†
*Pooled patient data from PALACE 1-3; includes all randomized patients with dactylitis (baseline dactylitis count >0; n = 633). Resolution was defined as a dactylitis count of 0.
†LOCF; for patients who qualified for early escape at week 16, the week 16 value was carried forward.
BID, twice daily; LOCF, last observation carried forward; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
